ClinConnect ClinConnect Logo
Search / Trial NCT06589687

The Patient AS EDUcator in Anesthesia: Exploring the Patients' Experience During and After Unexpected Cesarean Delivery Under Neuraxial Anesthesia to Inform Anesthetic Practice

Launched by SAMUEL LUNENFELD RESEARCH INSTITUTE, MOUNT SINAI HOSPITAL · Sep 6, 2024

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Cesarean Delivery Patient Experience Epidural

ClinConnect Summary

This clinical trial, titled "The Patient AS EDUcator in Anesthesia," is focused on understanding the experiences of women who have to undergo unexpected cesarean deliveries using a type of anesthesia called neuraxial anesthesia. The goal is to gather insights from both patients and healthcare providers to improve care during these urgent situations. By listening to patients' concerns and suggestions, the study aims to enhance their overall satisfaction and ensure they receive better care in the future.

To participate in this trial, women aged 18 and older who are having an emergency or urgent cesarean delivery may be eligible. This includes cases where there are serious concerns for the mother or baby's health, but it does not involve planned surgeries. Participants will be interviewed about their experiences, and their feedback will help create educational materials for healthcare teams involved in these procedures. This study is currently recruiting participants, and it emphasizes the importance of understanding patients' perspectives to improve care in similar situations moving forward.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • aged 18 years or older
  • English language proficiency (as interviews will be performed in English)
  • ASA Physical Classification Score 2-5 +/- E
  • Emergency or Urgent CD that can be done with the existing or newly applied neuraxial anesthesia (specifically, without the need for general anesthesia) due to fetal or maternal emergencies (e.g., fetal bradycardia, pre-eclampsia, chorioamnionitis, etc.)
  • uCD is defined as Level 1 (Emergency - Immediate threat to life of woman or fetus) and Level 2 (Urgent - Maternal or fetal compromise which is not immediately life-threatening) CD 16
  • Patients will be included if they undergo preterm delivery (under 37 weeks of gestation, or are having a multiple gestation pregnancy, also, if there is a significant fetal anomaly present
  • Exclusion criteria:
  • Under 18 years of age
  • Unable to answer questions due to a language barrier or because of their mental or physical state (e.g., intubated patients)
  • BMI at the time of delivery that falls in the super-morbidly obese category (BMI \> 55 kg/m2)
  • Patients who underwent preterm delivery (under 32 weeks gestation)
  • Patients will be excluded if neonatal death has occurred.
  • Patients who were scheduled for an elective CD will be excluded.

About Samuel Lunenfeld Research Institute, Mount Sinai Hospital

The Samuel Lunenfeld Research Institute at Mount Sinai Hospital is a leading biomedical research facility dedicated to advancing our understanding of human health and disease. Renowned for its innovative research programs, the institute focuses on areas such as cancer, genetics, and reproductive health, fostering collaboration among top-tier scientists and clinicians. With a commitment to translating research findings into clinical applications, the Samuel Lunenfeld Research Institute plays a pivotal role in the development of novel therapies and interventions, thereby contributing to improved patient outcomes and the advancement of medical science.

Locations

Toronto, Ontario, Canada

Patients applied

0 patients applied

Trial Officials

Sabine Nabecker, MD

Principal Investigator

MOUNT SINAI HOSPITAL

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported